Biocytogen and Whitehawk Partner to Advance Next-Generation Bispecific ADCs

The collaboration combines Biocytogen’s fully human antibody discovery platform with Whitehawk’s ADC expertise to develop novel cancer therapies with enhanced targeting potential.

Biocytogen and Whitehawk Therapeutics have entered into a global partnership to develop bispecific antibody-drug conjugates (BsADCs), combining antibody engineering and targeted cancer drug delivery technologies.

The collaboration aims to identify new ADC candidates by pairing Biocytogen’s bispecific antibody capabilities with Whitehawk’s proprietary antibody-drug conjugate (ADC) linker-payload platform.

Combining Antibody Engineering with ADC Innovation

Under the agreement, Biocytogen will provide access to up to five bispecific antibodies generated through its RenLite platform.

Whitehawk will evaluate these antibody candidates alongside its own ADC technologies to identify potential BsADC programmes with differentiated therapeutic profiles.

Following evaluation, Whitehawk will have the option to advance selected candidates into its development pipeline.

If Whitehawk chooses to proceed with any resulting BsADC programmes, it will retain global rights and full control over further development activities.

Targeting the Next Generation of Cancer Therapies

Bispecific ADCs represent an emerging approach in oncology by combining two targeted antibody binding sites with the cancer-killing capabilities of ADC technology.

Traditional ADCs use antibodies to deliver cytotoxic payloads directly to tumour cells, while bispecific antibodies are designed to recognise multiple targets or improve tumour selectivity.

By combining these approaches, companies hope to improve precision, overcome treatment resistance and expand the number of cancers that can be effectively targeted.

RenLite Platform Supports Bispecific Antibody Development

Biocytogen’s RenLite platform uses a common light-chain antibody design to support the discovery and optimisation of fully human bispecific antibodies.

The approach is intended to reduce the risk of light-chain mispairing, a technical challenge that can affect the development and manufacturing of bispecific antibody therapies.

Through the partnership, Biocytogen will contribute its antibody discovery capabilities, while Whitehawk will apply its expertise in ADC development and oncology drug discovery.

Deal Structure and Commercial Terms

Financial terms include an upfront payment to Biocytogen, with the company also eligible for additional payments linked to development, regulatory and commercial milestones.

Biocytogen will additionally receive low single-digit royalties on net sales of any commercial products resulting from the collaboration.

Further financial details were not disclosed.

Expanding Interest in ADC Platforms

The partnership reflects continued industry investment in ADC technologies, which have become one of the fastest-growing areas of oncology drug development.

Pharmaceutical companies are increasingly pursuing next-generation ADC approaches designed to improve tumour targeting, increase efficacy and address resistance to existing therapies.

For Biocytogen, the collaboration expands the potential applications of its bispecific antibody platform beyond standalone antibody therapeutics.

For Whitehawk, the partnership provides access to additional antibody candidates that could strengthen its ADC pipeline.

Why the Partnership Matters

The collaboration highlights several important trends in oncology innovation:

• Bispecific antibodies and ADCs are increasingly being combined to create more targeted cancer therapies.

• Biotech partnerships are accelerating access to specialised discovery platforms.

• Companies are seeking differentiated approaches to overcome limitations of existing oncology treatments.

• ADC technology remains a major focus for investment across the pharmaceutical industry.
  

Summary

Biocytogen and Whitehawk Therapeutics have partnered to develop bispecific antibody-drug conjugates by combining Biocytogen’s RenLite antibody platform with Whitehawk’s ADC expertise.

The collaboration aims to generate differentiated cancer therapies with improved targeting capabilities, adding to the growing momentum behind next-generation oncology platforms.

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com